Publications by authors named "Cristina Terlizzi"

The chicken embryo has emerged as a valuable model for preclinical studies due to its unique combination of accessibility, affordability, and relevance to human biology. Its rapid development, external growth environment, and clear structural visibility offer distinct advantages over traditional mammalian models. These features facilitate the study of real-time biological processes, including tissue development, tumor growth, angiogenesis, and drug delivery, using various imaging modalities, such as optical imaging, magnetic resonance imaging, positron emission tomography, computed tomography, and ultrasound.

View Article and Find Full Text PDF

Background: Oncogene-driven NSCLC is usually treated with targeted therapies using tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways, affecting tumor survival and proliferation. EGFR- and KRAS-mutant NSCLCs are the most represented subtypes, and they are treated in clinical practice with oncogene-targeting drugs in the first and second line, respectively. Unfortunately, the development of oncogene-independent resistant clones limits TKI efficacy.

View Article and Find Full Text PDF

Introduction: Neutrophil extracellular traps (NETs) are complex structures released by activated neutrophils that may modulate different steps of the metastatic cascade. The aim of our study was to investigate how NETs can modulate the adhesion properties of cancer cells and whether cell exposure to NETs can activate the epithelial-to-mesenchymal transition (EMT) program thus enhancing the migratory and invasive properties of tumor cells.

Materials And Methods: Different cancer cell lines were subjected to a solid-phase adhesion assay using NET-coated plates with or without the addition of antibodies against α5β1 or CCDC25 receptor.

View Article and Find Full Text PDF

Background: ATM is a multifunctional serine/threonine kinase that in addition to its well-established role in DNA repair mechanisms is involved in a number of signaling pathways including regulation of oxidative stress response and metabolic diversion of glucose through the pentose phosphate pathway. Oncogene-driven tumorigenesis often implies the metabolic switch from oxidative phosphorylation to glycolysis which provides metabolic intermediates to sustain cell proliferation. The aim of our study is to elucidate the role of ATM in the regulation of glucose metabolism in oncogene-driven cancer cells and to test whether ATM may be a suitable target for anticancer therapy.

View Article and Find Full Text PDF

We review the literature on the little-known roles of specific CaMKs in regulating endocrine functions of the pineal gland, the pituitary gland, and the hypothalamus. Melatonin activates hippocampal CaMKII, which then influences dendritogenesis. In the pituitary gland, the signal pathways activated by the CaMK in lower vertebrates, such as fishes, differ from those of mammals.

View Article and Find Full Text PDF

COVID-19 pandemic had a great impact on health systems and cancer care worldwide. Patients with cancer who develop COVID-19 are at high risk of severe outcomes and clarifying the determinants of such vulnerability of cancer patients would be of great clinical benefit. While the mechanisms of SARS-CoV-2 infection have been elucidated, the pathogenetic pathways leading to severe manifestations of the disease are largely unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers tested if targeting glucose metabolism and oncogene drivers together could improve the effectiveness of tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) cells.
  • They specifically downregulated pyruvate dehydrogenase kinase 1 (PDK1) in NSCLC cell lines and treated them with various TKIs to assess changes in metabolism and apoptosis.
  • Results showed that while PDK1 knockdown alone didn't significantly alter glucose metabolism, it enhanced mitochondrial respiration and apoptosis when combined with TKIs, indicating that targeting PDK1 could boost TKI efficacy by disrupting key protein complexes.
View Article and Find Full Text PDF
Article Synopsis
  • Notch1 is important for the transition of cells during cancer progression (EMT) and helps maintain cancer stem cells, suggesting it plays a significant role in lung cancer dynamics.
  • The study investigated whether high levels of activated Notch1 in lung cancer cells could shift their reliance from the EGFR pathway to the Notch1 pathway, potentially leading to resistance against EGFR inhibitors.
  • Results showed that tumor spheres (cancer stem cells) exhibited higher resistance to EGFR inhibitors, with increased Notch1 signaling and decreased EGFR levels, indicating a possible mechanism behind the observed therapeutic resistance in NSCLC.
View Article and Find Full Text PDF
Article Synopsis
  • Novel immunotherapy strategies like immune checkpoint blockade show promise in cancer treatment but only a small percentage of patients experience long-term success, highlighting the need for better patient selection.
  • *Despite various proposed biomarkers, none reliably predict which patients will respond to these treatments, suggesting the necessity for improved methods.
  • *Preclinical imaging studies focusing on developing tracers for visualizing immunotherapy targets may provide effective predictive biomarkers, and selecting appropriate animal models is crucial for translating these findings to clinical settings.
View Article and Find Full Text PDF
Article Synopsis
  • Preclinical imaging with radiolabeled probes is crucial for noninvasive testing of the efficacy of targeted cancer therapies and for identifying imaging markers that help monitor treatment responses in patients.
  • The review emphasizes the importance of targeting specific patient populations that express genetic alterations to maximize the success of clinical trials for these therapies.
  • Studies using various radiolabeled tracers have shown potential in assessing tumor responses, overcoming drug resistance, and facilitating patient selection for immunotherapy based on imaging results.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers tested if the drug imatinib could change how leukemia cells fueled themselves by altering key enzymes in glucose metabolism and mitochondrial function.
  • After treating leukemia cells with imatinib, they observed decreased levels of proteins that promote glycolysis and increased markers of oxidative phosphorylation.
  • These changes resulted in reduced glucose consumption and lactate production, while increasing ATP levels, suggesting a potential new strategy for targeting both BCR-ABL and mitochondrial functions in leukemia treatment.*
View Article and Find Full Text PDF
Article Synopsis
  • Researchers tested different cancer cell lines to see how well they could attach to NETs, focusing on the expression of various integrins.
  • They discovered that certain integrins, particularly α5β1, αvβ3, and αvβ5, improve cancer cell adhesion to NETs, while low levels of α5β1 hinder it; a cyclic peptide was found to block this adhesion by competing with fibronectin in NETs.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate how well F-fluorothymidine (F-FLT) PET/CT imaging can identify the effects of combining EGFR and MET inhibitors in treating non-small cell lung cancer (NSCLC).
  • Researchers treated NSCLC cells and mice with these inhibitors individually and in combination, and observed significant decreases in tumor viability and F-FLT uptake with the combination treatment, indicating better effectiveness.
  • The enhanced treatment effectiveness was linked to the inositol trisphosphate receptor type 3 (IP3R3), which interacted with K-Ras, revealing a mechanism for the improved efficacy of the drug combination.
View Article and Find Full Text PDF

Preclinical imaging with radiolabeled probes became an integral part of the complex translational process that moves a newly developed compound from laboratory to clinical application. Imaging studies in animal tumor models may be undertaken to test a newly synthesized tracer, a newly developed drug or to interrogate, in the living organism, specific molecular and biological processes underlying tumor growth and progression. The aim of the present review is to outline the current knowledge and future perspectives of preclinical imaging in oncology by providing examples from recent literature.

View Article and Find Full Text PDF